Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Immunocore Holdings. The associated price target is $60.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tyler Van Buren’s rating is based on a comprehensive analysis following Immunocore’s third-quarter earnings report. Despite a minor adjustment in the revenue forecast for Kimmtrak in 2025, the overall outlook remains positive, with a projected revenue of $405 million.
The decision to maintain a Buy rating and a DCF-based price target of $60 per share reflects confidence in the company’s financial health and future growth potential. These factors indicate a favorable investment opportunity, justifying the Buy recommendation.
In another report released on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.